Abstrakt

Przypisy

• 1. Bode-Böger S.M., Böger R.H., Kienke S., Junker W., Frölich J.C.:Elevated L-arginine/dimethylarginine ratio contributes to enhancedsystemic NO production by dietary L-arginine in hypercholesterolemicrabbits. Biochem. Biophys. Res. Commun., 1996; 219: 598-603
  Google Scholar
• 2. Böger R.H., Bode-Böger S.M., Szuba A., Tsao P.S., Chan J.R., TangphaoO., Blaschke T.F., Cooke J.P.: Asymmetric dimethylarginine(ADMA): a novel risk factor for endothelial dysfunction: its role inhypercholesterolemia. Circulation, 1998; 98: 1842-1847
  Google Scholar
• 3. Böger R.H., Lentz S.R., Bode-Böger S.M., Knapp H.R., Haynes W.G.:Elevation of asymmetrical dimethylarginine may mediate endothelialdysfunction during experimental hyperhomocyst(e)inaemia inhumans. Clin. Sci., 2001; 100: 161-167
  Google Scholar
• 4. Böger R.H., Zoccali C.: ADMA: a novel risk factor that explainsexcess cardiovascular event rate in patients with end-stage renaldisease. Atheroscler. Suppl., 2003; 4: 23-28
  Google Scholar
• 5. Botros M., Sikaris K.A.: The de ritis ratio: the test of time. Clin.Biochem. Rev., 2013; 34: 117-130
  Google Scholar
• 6. Bulau P., Zakrzewicz D., Kitowska K., Leiper J., Gunther A., GrimmingerF., Eickelberg O.: Analysis of methylarginine metabolism inthe cardiovascular system identifies the lung as a major source ofADMA. Am. J. Physiol. Lung Cell Mol. Physiol., 2007; 292: L18-L24
  Google Scholar
• 7. Eiselt J., Rajdl D., Racek J., Vostrý M., Rulcová K., Wirth J.: Asymmetricdimethylarginine and progression of chronic kidney disease:a one-year follow-up study. Kidney Blood Press Res., 2014; 39: 50-57
  Google Scholar
• 8. Esterbauer H., Schaur R.J., Zollner H.: Chemistry and biochemistryof hydroxynonenal, malonaldehyde and related aldehydes. FreeRadic. Biol. Med., 1991; 11: 81-128
  Google Scholar
• 9. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Böger S.M.,Haller H., Ritz E.: Asymmetric dimethylarginine and progression ofchronic kidney disease: the mild to moderate kidney disease study.J. Am. Soc. Nephrol., 2005; 16: 2456-2461
  Google Scholar
• 10. Forbes S.P., Druhan L.J., Guzman J.E., Parinandi N., Zhang L.,Green-Church K.B., Cardounel A.J.: Mechanism of 4-HNE mediatedinhibition of hDDAH-1: implications in NO regulation. Biochemistry,2008; 47: 1819-1826
  Google Scholar
• 11. Haase-Fielitz A., Bellomo R., Devarajan P., Story D., MatalanisG., Dragun D., Haase M.: Novel and conventional serum biomarkerspredicting acute kidney injury in adult cardiac surgery – a prospectivecohort study. Crit. Care Med., 2009; 37: 553-560References
  Google Scholar
• 12. Hsu C.P., Hsu P.F., Chung M.Y., Lin S.J., Lu T.M.: Asymmetric dimethylarginineand1long-term adverse cardiovascular events inpatients with type 2 diabetes: relation with the glycemic control.Cardiovasc. Diabetol., 2014; 13: 156
  Google Scholar
• 13. Kielstein J.T., Martens-Lobenhoffer J., Vollmer S., Bode-BögerS.M.: L-Arginine, ADMA, SDMA, creatinine, MDRD formula-detourto renal function testing. J. Nephrol., 2008; 21: 959-961
  Google Scholar
• 14. Koch A., Weiskirchen R., Kunze J., Dückers H., Bruensing J.,Buendgens L., Matthes M., Luedde T., Trautwein C., Tacke F.: Elevatedasymmetric dimethylarginine levels predict short- and long-termmortality risk in critically ill patients. J. Crit. Care, 2013; 28: 947-953
  Google Scholar
• 15. Mourad J.J., des Guetz G., Debbabi H., Levy B.I.: Blood pressurerise following angiogenesis inhibition by bevacizumab. A crucial rolefor microcirculation. Ann. Oncol., 2008; 19: 927-934
  Google Scholar
• 16. Nijveldt R.J., Teerlink T., Van Der Hoven B., Siroen M.P., KuikD.J., Rauwerda J.A., van Leeuwen P.A.: Asymmetrical dimethylarginine(ADMA) in critically ill patients: high plasma ADMA concentrationis an independent risk factor of ICU mortality. Clin. Nutr.,2003; 22: 23-30
  Google Scholar
• 17. Pope A.J., Druhan L., Guzman J.E., Forbes S.P., Murugesan V., LuD., Xia Y., Chicoine L.G., Parinandi N.L., Cardounel A.J.: Role of DDAH- 1 in lipid peroxidation product-mediated inhibition of endothelialNO generation. Am. J. Physiol. Cell Physiol., 2007; 293: C1679-C1686
  Google Scholar
• 18. Stary J., Zimmermann M., Campbell M., Castillo L., Dibar E.,Donska S., Gonzalez A., Izraeli S., Janic D., Jazbec J., Konja J., KaiserovaE., Kowalczyk J., Kovacs G., Li C.K., et al.: Intensive chemotherapyfor childhood acute lymphoblastic leukemia: results of therandomized intercontinental trial ALL IC-BFM 2002. J. Clin. Oncol.,2014; 32: 174-184
  Google Scholar
• 19. Sulicka J., Surdacki A., Strach M., Kwater A., Gryglewska B.,Ćwiklińska M., Balwierz W., Grodzicki T.K.: Elevated asymmetric dimethylargininein young adult survivors of childhood acute lymphoblasticleukemia: a preliminary report. Dis. Markers, 2012; 33: 69-76
  Google Scholar
• 20. Vallance P., Leone A., Calver A., Collier J., Moncada S.: Accumulationof an endogenous inhibitor of nitric oxide synthesis in chronicrenal failure. Lancet, 1992; 339: 572-575
  Google Scholar

Pełna treść artykułu